Screening for Fabry Disease in Kidney Transplant Recipients: Experience of a Multidisciplinary Team.

Abstract

Fabry disease (FD) is a rare cause of end-stage renal disease requiring kidney transplantation. Data on the incidence of unrecognized FD in kidney transplant recipients are scarce and probably underestimated. This study evaluated the incidence of FD in a population of kidney recipients, with a particular focus of the multidisciplinary approach for an early clinical assessment and therapeutic approach. Two hundred sixty-five kidney transplant recipients were screened with a genetic analysis for α-galactosidase A (GLA) mutation, with measurement of α-Gal A enzyme activity and Lyso Gb3 levels. Screening was also extended to relatives of affected patients. Seven patients (2.6%) had a GLA mutation. Two patients had a classic form of FD with Fabry nephropathy. Among the relatives, 15 subjects had a GLA mutation, and two had a Fabry nephropathy. The clinical and diagnostic assessment was completed after a median of 3.2 months, and mean time from diagnosis to treatment was 4.6 months. This study reported a high incidence of unrecognized GLA mutations in kidney transplant recipients. Evaluation and management by a multidisciplinary team allowed for an early diagnosis and treatment, and this would result in a delay in the progression of the disease and, finally, in better long-term outcomes.

• Authors: Massimiliano Veroux, Ines P Monte, Margherita S Rodolico, Daniela Corona, Rita Bella, Antonio Basile, Stefano Palmucci, Maria L Pistorio, Giuseppe Lanza, Concetta De Pasquale, Pierfrancesco Veroux
• Journal: Biomedicines (Biomedicines) Vol. 8 Issue 10 (Oct 07 2020) ISSN: 2227-9059 [Print] Switzerland
• PMID: 33036343 (Publication Type: Journal Article)